Rite Aid Corporation (NYSE: RAD) reported a narrower loss in the second quarter of 2021. Net loss shrank to $0.25 per share in the recently ended quarter from $1.49 per share in the prior-year quarter.
Revenue increased by 11.5% to $5.98 billion in Q2. The increase in revenues was driven by growth at both the Retail Pharmacy and Pharmacy Services segments. Analysts had expected Rite Aid to report breakeven earnings on revenue of $5.74 billion.
RAD stock was trading up about 1% during pre-market trading hours.
For fiscal 2021, the drugstore chain expects adjusted net (loss) income per share to be between $(0.67) and $0.09. Revenue is targeted to be between $23.5 billion and $24.0 billion with same store sales growth of 3% to 4% over fiscal 2020.
Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated
The healthcare sector is going through a phase of consolidation, creating fresh opportunities for emerging companies in a market that is slowly recovering from the pandemic. Several pharmaceuticals firms have
Shares of American Airlines Group (NASDAQ: AAL) have gained 42% since the beginning of this year and 50% over the past 12 months. Despite this, there is a mixed sentiment